Fentanyl products in the management of episodic pain in the cancer patient

References

• Portenoy RK. Treatment of cancer pain. Lancet. 2011;377:2236–2247.
   Google Scholar
• Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273–281.
   Google Scholar
• Mercadante S, Radbruch L, Caraceni A, et al. Steering committee of the european association for palliative care (EAPC) research network. Cancer. 2002;94:832–839.
   Google Scholar
• Løhre ET, Klepstad P, Bennett MI, et al. From “Breakthrough” to “Episodic” cancer pain? A European association for palliative care research network expert delphi survey toward a common terminology and classification of transient cancer pain exacerbation. J Pain Symptom Manage. 2016;51:1013–1019.
   Google Scholar
• Portenoy RK, Payne D, Jacobson P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129–134.
   Google Scholar
• Mercadante S, Lazzari M, Reale C, et al.; IOPS Study Group. Italian Oncological Pain Survey (IOPS): a multicentre Italian study of breakthrough pain performed in different settings. Clin J Pain. 2015;31:214–221.
   Google Scholar
• Davies A, Buchanan A, Zeppetella G, et al. cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage. 2013;46:619–628.
   Google Scholar
• Mercadante S, Adile C, Torta R, et al. Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients. Curr Med Res Opin. 2013;29:93.
   Google Scholar
• Mercadante S, Marchetti P, Cuomo A, et al.; IOPS MS study Group. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group. Support Care Cancer. 2016;24:961–968.
   Google Scholar
• Mercadante S, Villari P, Ferrera P, et al. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage. 2004;28:505–510.
   Google Scholar
• Mercadante S, Portenoy RK. Breakthrough cancer pain: twenty years of study. Pain2016Sep19. Epub ahead of print DOI:10.1097/j.pain.0000000000000721.
   Google Scholar
• Zeppetella G. Dynamics of breakthrough pain vs pharmacokinetics of oral morphine: implications for management. Eur J Cancer Care. 2009;18:331–337.
   Google Scholar
• Mercadante S. Intravenous morphine for management of cancer pain. Lancet Oncol. 2010;11:484–489.
   Google Scholar
• Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012;72:181–190.
   Google Scholar
• Rogríguez D, Urrutia G, Escobar Y, et al. Efficacy and safety of oral or nasal fentanyl for treatment of breakthrough pain in cancer patients: a systematic review. J Pain Palliat Care Pharmacother. 2015;29:228–246.
   Google Scholar
• Zeppetella G, Davies A, Eijgelshoven I, et al. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manage. 2014;47:772–785.
   Google Scholar
• Garnock-Jones KP. Fentanyl buccal soluble film: a review in breakthrough cancer pain. Clin Drug Investig. 2016;36:413–419.
   Google Scholar
• Hanks GW, Nugent M, Higgs CM, et al. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term study. Palliat Med. 2004;18:698–704.
   Google Scholar
• Payne R, Coluzzi P, Hart L, et al. Long-term safety of transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage. 2001;22:575–583.
   Google Scholar
• Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer. 2009;115:2571–2579.
   Google Scholar
• Rauck R, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877–2885.
   Google Scholar
• Nalamachu SR, Narayana A, Janka L. Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients. Curr Med Res Opin. 2011;27:751–760.
   Google Scholar
• Portenoy RK, Raffaeli W, Torres L, et al. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients. J Opioid Manage. 2010;6:319–328.
   Google Scholar
• Radbruch L, Torres LM, Ellershaw JE, et al. Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Support Care Cancer. 2012; 20:565.
   Google Scholar
• Mercadante S, Vellucci R, Cuomo A, et al. Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. Support Care Cancer. 2015;23:1349–1354.
   Google Scholar
• Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer. 2007;96:1828–1833.
   Google Scholar
• www.nice.org.uk/cg140
   Google Scholar
• Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs.oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage. 2013;46:573–580.
   Google Scholar
• Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev. 2013 Oct 21;(10):CD004311.
   Google Scholar
• Bedard G, Hawley P, Zhang L, et al. A survey of Canadian cancer patients’ perspectives on the characteristics and treatment of breakthrough pain. Support Care Cancer. 2013;21:2557–2563.
   Google Scholar
• Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the science committee of the association for palliative medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331–338.
   Google Scholar
• Mercadante S. Breakthrough pain: on the road again. Eur J Pain. 2009;13:329–330.
   Google Scholar
• Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol. 2011;80:460–465.
   Google Scholar
• Mercadante S. Rapid onset opioids for breakthrough pain: titrating or not titrating, this is the question. Eur J Pain. 2011;(Suppl. 2):443–448.
   Google Scholar
• Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage. 2008;35:563–567.
   Google Scholar
• Davies AN, Vriens J, Kennett A, et al. An observational study of oncology patients’ utilization of breakthrough pain medication. J Pain Symptom Manage. 2008;35:406–411.
   Google Scholar
• Mercadante S, Gatti A, Porzio G, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin. 2012;28:963–968.
   Google Scholar
• Mercadante S, Aielli F, Adile C, et al. fentanyl pectin nasal spray versus oral morphine in doses proportional to the basal opioid regimen for the management of breakthrough cancer pain: a comparative study. J Pain Symptom Manage. 2016;52:27–34.
   Google Scholar
• Mercadante S, Adile C, Cuomo A, et al. Fentanyl Buccal tablet vs. oral morphine in doses proportional to the basal opioid regimen for the management of breakthrough cancer pain: a randomized, crossover, comparison study. J Pain Symptom Manage. 2015;50:579–586.
   Google Scholar
• Mercadante S, Radbruck L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomized, crossover trial. Curr Med Res Opin. 2009;25:2805–2815. DOI:10.1185/03007990903336135
   Google Scholar
• Mercadante S, Prestia G, Adile C, et al. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen. J Pain. 2014;15:602–607.
   Google Scholar
• Mitigation strategies. Available from: https://www.tirfremsaccess.com/TirfUI/rems/home.action).
   Google Scholar
• Mercadante S, Caruselli A, Meli MR, et al. Patients’ acceptability of different fentanyl products for breakthrough cancer pain. Clin Oncol (R Coll Radiol). 2014;26:806.
   Google Scholar
• England R, Maddocks M, Manderson C, et al. How practical are transmucosal fentanyl products for breakthrough cancer pain? novel use of placebo formulations to survey user opinion. BMJ Support Palliat Care. 2011;1:349–351.
   Google Scholar
• Osborne V, Layton D, Fogg C, et al. Utilization of fentanyl buccal tablets in England: exploring off-label use reported in a cohort study. Eur J Pain. 2014;18:506–512.
   Google Scholar